A disease-specific therapy in facioscapulohumeral muscular dystrophy.
- Resource Type
- Academic Journal
- Authors
- Voermans N; Department of Neurology, Radboudumc Research Institute for Medical Innovation, Nijmegen, Netherlands.; Vissing J; Copenhagen Neuromuscular Center, Department of Neurology, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark. Electronic address: john.vissing@regionh.dk.
- Source
- Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 101139309 Publication Model: Print Cited Medium: Internet ISSN: 1474-4465 (Electronic) Linking ISSN: 14744422 NLM ISO Abbreviation: Lancet Neurol Subsets: MEDLINE
- Subject
- Language
- English
Competing Interests: NV is currently on the advisory board for facioscapuloperoneal muscular dystrophy for Fulcrum Therapeutics (the sponsor of Tawil and colleagues’ trial) and is the principal investigator on clinical trials for facioscapuloperoneal muscular dystrophy for Fulcrum Therapeutics. JV has consulted on advisory boards related to facioscapuloperoneal muscular dystrophy for Roche, Fulcrum Therapeutics, and Dyne Therapeutics, and is the principal investigator on clinical trials for facioscapuloperoneal muscular dystrophy for Fulcrum Therapeutics and Roche.